Status:
UNKNOWN
The MOTIVE-PSP Initiative (Progressive Supranuclear Palsy)
Lead Sponsor:
University of Salerno
Collaborating Sponsors:
Azienda Ospedaliera di Padova
Azienda Ospedaliero, Universitaria Pisana
Conditions:
Progressive Supranuclear Palsy
Eligibility:
All Genders
40+ years
Brief Summary
Progressive Supranuclear Palsy (PSP) is a rapidly progressive neurodegenerative disease characterized by falls and oculomotor disturbances. Several clinical trials are currently evaluating the efficac...
Detailed Description
Hyphotesis and Significance: 1)Cross-sectional phase:verify if specific motor, cognitive, language, cerebrospinal fluid (CSF) and imaging assessments represent reliable biomarkers of diagnosis in PSP...
Eligibility Criteria
Inclusion
- Diagnosis of Progressive Supranuclear Palsy based on current available clinical criteria
- ability to walk for at least 5 steps
Exclusion
- Comorbidities interfering with study assessments
- Significant MRI abnormalities as cerebrovascular diseases, tumors.
Key Trial Info
Start Date :
January 1 2022
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
January 1 2025
Estimated Enrollment :
165 Patients enrolled
Trial Details
Trial ID
NCT04691635
Start Date
January 1 2022
End Date
January 1 2025
Last Update
February 11 2022
Active Locations (3)
Enter a location and click search to find clinical trials sorted by distance.
1
AOU Padova
Padua, Italy
2
AOU Pisa
Pisa, Italy
3
AOU San Giovanni di Dio e Ruggi d'Aragona
Salerno, Italy, 84131